AI Article Synopsis

  • The study investigates the roles of different adenosine receptors (A1R, A2AR, A2BR, A3R) in liver fibrosis, noting that A1R and A2AR may worsen the condition while A2BR and A3R could help alleviate it.
  • Using mouse models of liver fibrosis, various adenosine receptor agonists were tested, showing that A1R and A2AR activation increases liver damage and cellular proliferation, whereas A2BR and A3R activation helps reduce fibrosis symptoms.
  • The findings indicate that targeting specific adenosine receptors could be a potential therapeutic strategy for managing liver fibrosis, with NECA, an adenosine analog, showing promising results in reducing fibrosis and

Article Abstract

Background: The adenosine-adenosine receptor pathway plays important roles in the immune system and inflammation. Four adenosine receptors (i.e., A1R, A2AR, A2BR, and A3R) have been identified. However, the roles of these receptors were different in the disease progress and even play opposite roles in the same disease. This study aims to investigate the roles of A1R/A2AR/A2BR/A3R activation in liver fibrosis.

Methods: Intraperitoneal injection of CCl into C57BL/6 mice was used to induce liver fibrosis in the models. Adenosine receptor agonists CCPA, CGS21680, BAY 60-6583, and namodenoson were used for A1R/A2AR/A2BR/A3R activation, respectively. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were used to evaluate the liver function. Hematoxylin and eosin (H&E) staining was used to investigate the pathological damage. Masson staining and Sirius Red staining were performed to evaluate the degree of collagen deposition. CCK8 and scratch assays were used to investigate the proliferation and migration ability of hepatic stellate cells (HSCs).

Results: By using liver fibrosis mouse models, we observed that the A1R and A2AR agonists aggravated liver fibrosis, characterized by increasing ALT and AST levels, more serious liver pathological damage, and collagen deposition. However, the A2BR and A3R agonists alleviated liver fibrosis. Moreover, the A1R and A2AR agonist treatment promotes the proliferation and migration of HSC line LX2, while A2BR and A3R agonist treatment inhibited LX2 proliferation and migration. Consistently, A1R and A2AR agonist treatment elevated the expression of α-SMA and Col1α1 in LX2, whereas A2BR and A3R agonist treatment inhibited the expression of α-SMA and Col1α1 in LX2 cells. Additionally, 5'-N-ethyl-carboxamidoadenosine (NECA), a metabolically stable adenosine analog, alleviated liver fibrosis and inhibited LX2 cell activity, proliferation, and migration.

Conclusion: This study demonstrated the different roles of A1R/A2AR/A2BR/A3R during liver fibrosis development via regulating the HSC activity and proliferation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11405188PMC
http://dx.doi.org/10.3389/fphar.2024.1424624DOI Listing

Publication Analysis

Top Keywords

liver fibrosis
28
a1r a2ar
16
a2br a3r
16
agonist treatment
16
proliferation migration
12
liver
10
adenosine receptors
8
roles a1r/a2ar/a2br/a3r
8
a1r/a2ar/a2br/a3r activation
8
ast levels
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!